Navigation Links
Proof of Concept Study Shows Protection with Influenza Vaccine
Date:4/24/2013

COLUMBIA, Md., April 24, 2013 /PRNewswire/ -- Royal DSM, a global life sciences and materials sciences company, announced today the results of a proof of concept study that demonstrated efficacy of an influenza vaccine developed and produced by a commercial microalgal platform system. The study results were published today in the peer-reviewed journal, PLOS ONE. In this study, the researchers used DSM's proprietary Schizochytrium platform to produce a subunit influenza vaccine capable of preventing disease in mice. Schizochytrium is currently used to produce nutritional lipids for supplements and fortification of foods. The vaccine was made using this basic commercial process, which is faster and less expensive than other comparable pharmaceutical processes.

"Higher-yield, lower-cost, and faster influenza vaccine production processes are critical to meet the global supply and surge production capabilities needed to counter global epidemic and pandemic threats," says Casey Lippmeier , a senior scientist at DSM who led the study.

This new Schizochytrium cell-based process has the potential to reduce vaccine scale-up and manufacture to less than half the time of the current egg-based system.  Traditionally, common influenza vaccines have been created from inactivated or attenuated preparations of live virus cultured in chicken eggs.  The current egg-based system is a labor intensive process requiring one or two eggs per vaccine dose and more than six months to scale-up for commercial manufacturing. 

"This production system facilitates development of new flu vaccines with earlier availability ahead of flu season, multivalent formulations for protection against a greater number of flu strains, and potentially better matching of the flu vaccine to the strains circulating in a given year," said Lippmeier.

Proof of Concept Study
The published study, Vaccination against Influenza with Recombinant Hemagglutinin Expressed by Schizochytrium sp. Confers Protective Immunity, can be found online at  http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0061790.  In this study, recombinant hemagglutinin proteins of influenza virus were expressed in the microalga Schizochytrium sp., an established, fermentable organism which is routinely grown in large commercial scale (>150,000 L). Schizochytrium cells were capable of secreting full-length, membrane-bound, influenza proteins in a readily usable form for vaccine formulation. One recombinant hemagglutinin (rHA) protein derived from A/Puerto Rico/8/34 (H1N1) influenza virus was evaluated as a vaccine in a mouse challenge model.  Mice were vaccinated with a single dose of 1.7, 5 or 15 micrograms of rHA vaccine, with or without adjuvant, and then challenged with lethal levels of homologous H1N1 virus.  80-100% of the vaccinated mice survived the challenge.  Complete protection (100%) was achieved in all dose groups, with and without adjuvant, after a second vaccination.  These data demonstrate the potential of Schizochytrium sp. as a platform for the production of ready-to-use recombinant antigens for vaccination against influenza.

Schizochytrium
Schizochytrium sp. is a robustly fermentable eukaryote, best known for its ability to accumulate large amounts of cellular triglyceride containing nutritionally important polyunsaturated fatty acids (PUFA); most notably, docosahexaenoic acid (DHA). The majority of Schizochytrium-derived triglyceride oil is used to fortify foods with DHA. Schizochytrium biomass has also found use in animal applications, most commonly as a blend in poultry or aquaculture feeds to increase levels of DHA in eggs or farmed seafood, respectively. Ten tons of triglyceride oil have been produced per annum using Schizochytrium grown in fully defined, protein-free, liquid media exceeding 150,000 liter scale.  The organism is highly efficient at consuming nutrients in the presence of low dissolved oxygen levels, with a reported peak rate of 9 doublings per day. This productivity translates into lower energy, materials, and labor costs.  The oil derived from Schizochytrium are GRAS-approved with a history of beneficial use in both human and consumption.

DSM – Bright Science. Brighter Living .™
Royal DSM is a global science-based company active in health, nutrition and materials.  By connecting its unique competences in Life Sciences and Materials Sciences, DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders.  DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials.  DSM's 22,000 employees deliver annual net sales of around €9 billion.  The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

For more information:

DSM
Anthony Martin
tel. + 1 443-542-2599
Mobile - +1 410-818-6999
email anthony.martin@dsm.com

Forward-looking statements
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading. Although DSM has used diligent care to ensure that the information provided herein is accurate and up to date, this publication does not constitute or provide scientific or medical advice and is distributed without warranty of any kind, either expressly or implied.


'/>"/>
SOURCE Royal DSM
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
2. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
3. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
4. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
5. Proof of Concept Study Initial Findings
6. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
7. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
8. First Product in Tris Pharmas Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris
9. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
10. A New Audio Interview With Ronald Adams President Of Medical Alarm Concepts Holding, Inc., Is Now At SmallCapVoice.com
11. Medical Alarm Concepts Begins Shipments To Europe - Company Ordering Additional Inventory To Keep Up With Growing Demand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 The primary goal of this ... patterns on the usage of liquid biopsy. Key information ... - Timeframe of liquid biopsy adoption amidst future ... Evs—by organization type - Sample inflow to conduct liquid ... stool, serum, and so on. - Correlation analysis of ...
(Date:2/11/2016)... YORK , Feb. 11, 2016 ... instruments commonly used in laboratories. These may range from ... condensers. Laboratory glassware is made from borosilicate glass because ... Laboratory plasticware, on the other hand, started gaining popularity ... it was easier to replace glass with plastic in ...
(Date:2/11/2016)... DUNKIRK, N.Y. , Feb. 11, 2016  Governor ... Athenex that will create 1,400 jobs throughout ... by a partnership with the SUNY Polytechnic Institute, includes ... the Conventus Building in Buffalo , ... square foot manufacturing facility in Dunkirk ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited to ... Miami dental office. Beginning in January, Miami Dental Specialists will offer the non-metal implants ... the first office to be chosen by the dental implant manufacturer, Straumann, to bring ...
(Date:2/12/2016)... ... 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased ... upcoming Feb. 24 webinar that will discuss ways health plans and PBMs are ... the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to treat cholesterol. ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Central Coast Autism Spectrum Center (CCASC) invites teens ... provide a night of fun for teens with and without special needs to gather in ... included at the event. The dance will take place on Saturday, Feb. 13 from 7 ...
(Date:2/12/2016)... ... ... restorative dentistry, to date there has been no other option in the U.S. to stop ... a now a new protocol in stopping cavity progression; Silver Diamine Fluoride (SDF). With ... The application is as simple as drying the tooth and applying the SDF to the ...
(Date:2/11/2016)... Alpharetta, Georgia (PRWEB) , ... February 11, 2016 ... ... Physicians Group (DMPG) will use the action analytics leader’s population health solutions, ... analytics and clinical support to the Atlanta-area healthcare system. Details of the contract ...
Breaking Medicine News(10 mins):